The development of dose-dense adjuvant chemotherapy.

about

Complementary and alternative medicine use by patients receiving curative-intent chemotherapy.

P2860

Q47438382-37ECA21C-1D3B-45CC-8150-45529DAC8A30

P2860

The development of dose-dense adjuvant chemotherapy.

Item

http://www.wikidata.org/entity/Q38296287

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

The development of dose-dense adjuvant chemotherapy.

@en

type

Item

label

The development of dose-dense adjuvant chemotherapy.

@en

prefLabel

The development of dose-dense adjuvant chemotherapy.

@en

P1476

The development of dose-dense adjuvant chemotherapy.

@en

P2093

Chau Dang

http://www.w3.org/2001/XMLSchema#string

Clifford Hudis

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.

Adjuvant trastuzumab in HER2-positive breast cancer.

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

P304

42-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TBJ.12364

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25530009

http://www.w3.org/2001/XMLSchema#string

The development of dose-dense adjuvant chemotherapy.

about

P2860

P2860

The development of dose-dense adjuvant chemotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698